ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,495
0,00%
Bitcoin
97 662,85
-0,45%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Incannex Healthcare Ltd (IXHL)

  7. Incannex Healthcare Ltd (IXHL) Actualités

IXHL

Incannex Healthcare (IXHL)

Incannex Healthcare Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IXHL
DateHeureSourceTitreSymboleSociété
11/12/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
09/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IXHLIncannex Healthcare Ltd
06/12/202422h23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IXHLIncannex Healthcare Ltd
26/11/202422h06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IXHLIncannex Healthcare Ltd
14/11/202422h05GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
12/11/202412h07Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:IXHLIncannex Healthcare Ltd
12/11/202412h04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
06/11/202422h19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IXHLIncannex Healthcare Ltd
31/10/202421h10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202422h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202422h48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
24/10/202413h30GlobeNewswire Inc.Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical OfficerNASDAQ:IXHLIncannex Healthcare Ltd
30/09/202422h01GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
30/09/202413h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IXHLIncannex Healthcare Ltd
10/09/202414h00GlobeNewswire Inc.Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena InvestorsNASDAQ:IXHLIncannex Healthcare Ltd
10/09/202413h00Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IXHLIncannex Healthcare Ltd
05/08/202413h30GlobeNewswire Inc.FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to ProceedNASDAQ:IXHLIncannex Healthcare Ltd
30/07/202413h30GlobeNewswire Inc.Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42XNASDAQ:IXHLIncannex Healthcare Ltd
30/05/202413h30GlobeNewswire Inc.Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
07/05/202413h30GlobeNewswire Inc.Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorderNASDAQ:IXHLIncannex Healthcare Ltd
16/04/202414h00GlobeNewswire Inc.Incannex Healthcare Inc. Quarterly Update, Q1 2024NASDAQ:IXHLIncannex Healthcare Ltd
28/02/202413h30GlobeNewswire Inc.Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety DisorderNASDAQ:IXHLIncannex Healthcare Ltd
16/02/202413h30GlobeNewswire Inc.Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking CessationNASDAQ:IXHLIncannex Healthcare Ltd
14/02/202412h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IXHLIncannex Healthcare Ltd
01/02/202413h30GlobeNewswire Inc.Clarion Clinics Open for Psychedelic-Assisted TreatmentsNASDAQ:IXHLIncannex Healthcare Ltd
24/01/202422h05GlobeNewswire Inc.Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid ArthritisNASDAQ:IXHLIncannex Healthcare Ltd
18/01/202414h22GlobeNewswire Inc.Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis CommencesNASDAQ:IXHLIncannex Healthcare Ltd
17/01/202413h30GlobeNewswire Inc.Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
21/12/202322h05GlobeNewswire Inc.Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in AustraliaNASDAQ:IXHLIncannex Healthcare Ltd
20/12/202323h05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IXHLIncannex Healthcare Ltd
 Showing the most relevant articles for your search:NASDAQ:IXHL

Dernières Valeurs Consultées

EU
LR
Legrand
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
AMZN
Amazon.com
COIN
XRPUSD
Ripple
NASDAQ
NVDA
NVIDIA
EU
EN
Bouygues
EU
RNO
Renault
EU
ML
Michelin
COIN
AVAXUSD
Avalanche
EU
AF
Air FranceKLM
EU
HO
Thales
NYSE
NKE
Nike
EU
PX4
SBF 120
EU
DG
Vinci
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés